echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Lingke Pharmaceuticals Announces the Completion of the First Patient Dosing in the Phase II Clinical Study of LNK01001 in the Treatment of Atopic Dermatitis

    Lingke Pharmaceuticals Announces the Completion of the First Patient Dosing in the Phase II Clinical Study of LNK01001 in the Treatment of Atopic Dermatitis

    • Last Update: 2022-05-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Linkco Pharmaceuticals (Hangzhou) Co.
    , Ltd.
    (hereinafter referred to as “Linkco Pharmaceuticals”) is an innovative drug research and development company in the clinical stage
    .
    The company recently announced that the first patient has been dosed in a Phase II clinical trial of its selective JAK1 inhibitor LNK01001 for the treatment of autoimmune diseases in atopic dermatitis (AD)
    .
    This study is a clinical study evaluating the efficacy and safety of LNK01001 capsules in adult patients with moderate to severe atopic dermatitis
    .
    Atopic dermatitis is a chronic, relapsing, inflammatory skin disease that often occurs on the face, neck, and elbow fossa
    .
    Patients with moderate-to-severe atopic dermatitis have recurrent severe itching and chronic eczema-like skin lesions as the main clinical manifestations, and are often combined with other atopic diseases such as allergic rhinitis and asthma, which seriously affect the quality of life
    .
    LNK01001 is a new class 1 drug independently developed by Lingke Pharmaceuticals for the treatment of autoimmune diseases.
    It is currently in the clinical development stage.
    Previously, clinical phase II studies for rheumatoid arthritis and ankylosing spondylitis have been carried out.

    .
    The lead researcher of the study, Professor Zhang Jianzhong, director of the 13th session of the Dermatology Branch of the Chinese Medical Association, and director of the Department of Dermatology of Peking University People's Hospital, said: "Atopic dermatitis is a chronic disease, and the disease is often protracted and unhealed.
    It seriously affects the quality of life of patients, and also brings a huge burden and mental pressure to the patient's family and society; LNK01001 has shown good safety in the trial of healthy people, and we expect excellent efficacy and safety in the trial of patients
    .
    " Dr.
    Xueli Wang, Chief Medical Officer of Lingke Pharmaceutical, said: "Atopic dermatitis has profound negative impacts on the physical and mental health and economy of patients and their families, and it requires long-term disease management
    .
    LNK01001 is a very promising treatment for atopic dermatitis.
    As an innovative drug candidate for autoimmune diseases such as dermatitis, we will target the needs of patients and work with researchers to rapidly advance the clinical research of LNK01001 to benefit patients as soon as possible
    .
    "        
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.